US Patent

US11207324 — Treatment of HER2 positive cancers

Method of Use · Assigned to Seagen Inc · Expires 2038-04-27 · 12y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method for treating or ameliorating HER2 positive cancers in a subject using a combination therapy that includes an anti-HER2 antibody and tucatinib.

USPTO Abstract

In one aspect, the present invention provides a method for treating or ameliorating the effects of a HER2 positive cancer in a subject. In some embodiments, the method comprises administering a combination therapy comprising an anti-HER2 antibody and tucatinib. In some embodiments, the method further comprises administering a chemotherapeutic agent (e.g., an antimetabolite) to the subject. Pharmaceutical compositions and kits are also provided herein.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3783 — Tukysa
U-3783 — Tukysa

Patent Metadata

Patent number
US11207324
Jurisdiction
US
Classification
Method of Use
Expires
2038-04-27
Drug substance claim
No
Drug product claim
No
Assignee
Seagen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.